Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases 7,278 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay Siegall bought 7,278 shares of Immunome stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average cost of $20.48 per share, for a total transaction of $149,053.44. Following the purchase, the chief executive officer owned 860,525 shares of the company’s stock, valued at $17,623,552. The trade was a 0.85% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunome Trading Up 7.5%

Shares of Immunome stock opened at $21.44 on Monday. The firm has a market capitalization of $1.97 billion, a PE ratio of -7.27 and a beta of 2.17. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $25.30. The business’s 50-day moving average price is $17.68 and its 200-day moving average price is $12.73.

Immunome (NASDAQ:IMNM) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. As a group, analysts predict that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IMNM has been the topic of several recent research reports. Wedbush restated an “outperform” rating and issued a $21.00 price target on shares of Immunome in a research note on Friday, November 7th. Craig Hallum initiated coverage on shares of Immunome in a research report on Friday, September 5th. They issued a “buy” rating and a $26.00 target price for the company. Leerink Partners set a $40.00 price objective on shares of Immunome in a report on Monday, December 15th. Wall Street Zen raised shares of Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, Guggenheim upped their price objective on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.09.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Immunome by 43.4% in the first quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock valued at $28,987,000 after acquiring an additional 1,303,753 shares during the period. Principal Financial Group Inc. increased its holdings in Immunome by 222.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after acquiring an additional 762,147 shares in the last quarter. Woodline Partners LP raised its position in Immunome by 69.0% during the first quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock worth $11,157,000 after acquiring an additional 676,804 shares during the period. Driehaus Capital Management LLC acquired a new position in shares of Immunome during the 1st quarter worth about $4,109,000. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in Immunome in the 2nd quarter worth about $5,104,000. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.